Sareum Holdings PLC - Sareum to Participate in the Edison Open House
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum to Participate in the Edison Open House: Global Healthcare 2021
The following link can be used to register: https://www.lsegissuerservices.com/spark/edison-open-house-global-healthcare-2021
For further information, please contact:
Sareum Holdings plc
01223 497 700
Strand Hanson Limited (Nominated Adviser)
020 7409 3494
Hybridan LLP (Nominated Broker)
020 3764 2341
Citigate Dewe Rogerson (Financial PR)
020 7638 9571
About EOP:GH 2021
The Edison Open House: Global Healthcare 2021 (EOP:GH 2021) is a virtual conference with a mission - to open up access to the booming universe of healthcare stocks to the widest possible audience.
The event will explore the case for investing in a carefully curated selection of microcap stocks - as well as demystify the global megatrends behind the boom in healthcare investment which, in the third quarter of last year alone, saw a record
Thousands of institutions, family offices, wealth managers and individual investors - as well journalists, entrepreneurs and investment banks - will be hosted across the three days.
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
Quick facts: Sareum Holdings PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE